 |
May 13, 2024 |
|
Dear Advocate,
As we prepare to commemorate HIV Vaccine Awareness Day (HVAD) on May 18, the field continues to see some modest scientific breakthroughs, while still facing extraordinary challenges. Despite having an evolving toolbox of highly effective prevention options including new long-acting PrEP, we continue to see high HIV incidence in hard-hit corners of the world. Many advocates and researchers agree that ending the HIV epidemic globally without a vaccine will be extremely difficult—even with long-acting PrEP products on the market and more on the way.
|
| "This toolbox of PrEP options will hopefully be transformative, but it is critically important that we still prioritize a vaccine." – Nina Russell, Director of TB and HIV R&D, the Bill & Melinda Gates Foundation on the new PxPulse podcast |
|
Scroll through our list below for an exciting new podcast, HVAD webinars, and other key resources to mark HVAD 2024.
|
| HVAD Collection of Resources and Events |
|
|
| |
|
|
 |
|
|
| listen now |
 |
|
|
|
|
|
 |
Join the Choice Agenda to gain a broad understanding of the current landscape for HIV vaccines and what discovery medicine means for HIV vaccine research and development moving forward, with a focus on community and advocacy priorities.
|
|
|
|
|
|
|
 |
AVAC’s issue briefs, From the Lab to the Jab, cover the barriers to, and solutions for equitable access to vaccines in low- and middle-income countries. During this webinar, an expert panel will discuss lessons learned, an international initiative for vaccine development, and how research and access can be improved.
|
|
|
|
|
|
|
|
Communities across the globe are engaging in a wide array of events focused on HIV vaccine awareness. See our HVAD page for details on local and regional activities the Coalition to Accelerate & Support Prevention Research (CASPR) partners are leading.
Register for our partner, IAVI's webinar: Mapping Routes to Success in HIV Vaccine Development, on May 29, which will focus on strategies to advance the most promising HIV vaccine candidates toward clinical trials, emphasizing the shift toward localized research and development. It will also delve into the progression of experimental medicines, including germline targeting and other innovative approaches, from initial trials to gaining regulatory approval and community acceptance.
|
|
|
|
|
|
|
 |
20 years and 12 efficacy trials have delivered two positive signals for vaccines and bNAbs, but unfortunately many more flat results. This infographic provides this historical timeline and key information about each trial.
|
| download |
|
|
|
|
And, on the heels of last week’s HIV Vaccine Trials Network (HVTN) annual meeting, where much discussion surrounded the potential of role of bNAbs in prevention (see AVAC’s 2023 HVAD spotlight on bNABs) be sure to watch this space for more resources that unpack it all.
|
|
|
You're receiving this because you signed up for our newsletter. Not interested any longer?
Manage email preferences | Unsubscribe
|
|
|
